REDX PHARMA LIMITED

("Redx" or the "Company")

Redx joins panel of experts at the 8th IPF Summit in Boston

Alderley Park, UK, 20 August 2024 Redx Pharma (JPJ:REDX), the clinical-stage, biotechnology company focussed on discovering and developing novel, small molecule, targeted therapeutics for fibrotic disease and cancer will be presenting at the 8th Idiopathic Pulmonary Fibrosis (IPF) Summit, in Boston, USA, 20 – 22 August 2024.

The IPF Summit is the industry's largest drug development initiative for the pulmonary fibrosis community and the 2024 summit will focus on: *Harness Emerging Biological Understanding, Apply Novel & Evolving Models & Assess Patient Populations to Propel Innovative & Efficacious Pulmonary Fibrosis Therapeutics Through Phase 2 & Beyond*.

Dr Elaine Kilgour, Head of Translational Science at Redx, will join an expert panel as part of the pre-conference workshop C, titled: *Comparatively Assess Novel & Disease- Specific Targets vs. Upstream Broad-Spectrum Targets to Unveil Untapped Opportunities for Enhanced IPF Therapeutics*.

Dr. Kilgour will present selective ROCK2 inhibition as a potential target for the treatment of IPF and other fibrotic diseases. Redx is currently progressing zelasudil (RXC007), a next-generation, highly selective ROCK2 inhibitor with improved characteristics to unlock the antifibrotic potential of the disease pathway, through a Phase 2a clinical study in patients with IPF.

Details of the panel presentation are as follows:

Workshop C: Comparatively Assess Novel & Disease - Specific Targets vs. Upstream Broad-Spectrum Targets to Unveil Untapped Opportunities for Enhanced IPF Therapeutics
Redx Presentation Title: Zelasudil: Highly Specific ROCK2 Selective Inhibitor for IPF and Fibrotic Disease

Day/Date: Tuesday, August 20, 2024

Time: 11:30 – 13:30 EST

Location: Revere Hotel Boston Common, 200 Stuart St, Boston, MA, 02116, United States

Following the presentation, a copy of the presentation deck will be made available on the Company website at: https://www.redxpharma.com/scientific-publications/

About IPF

IPF is a debilitating disease of the lungs which progressively causes scarring and a reduction in lung function. Occurring primarily in older adults (>50 years old), it involves irreversible and variable scarring, stiffening, and thickening of the lung tissues, leading to patients experiencing shortness of breath and lack of oxygen absorption. Over 170,000 patients suffer with IPF[i] and around a further 53,000 people are diagnosed each year (US, 5 EU, Japan). Patients diagnosed with IPF have an estimated life expectancy of 3 to 5 years.[ii] There is no known cure and current treatment only slows progression of the disease.

For further information, please contact:

Redx Pharma Limited T: +44 (0)1625 469 918

UK Headquarters

Erin Hamid, Interim Head of Communications

ir@redxpharma.com

FTI Consulting T: +44 (0)203 727 1000

Simon Conway/ Ciara Martin

About Redx Pharma Limited

Redx Pharma (JPJ: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry leading ROCK inhibitor portfolio through the clinic, including zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis and RXC008, a GI-targeted pan-ROCK inhibitor for the treatment of fibrostenotic Crohns disease. Additionally, the Company has a Phase 2 precision oncology programme which it intends to partner for further development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated

targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.

---

[i] Patient numbers (diagnosed prevalence) & market size forecast data sourced from Global Data (US, EU5, Japan)

[ii] Clinical Estimates from Hyun 2015, Ley 2012, Raghu 2006